1) Bonelli RM, Aschoff A, Jirikowski G:Olanzapine for Huntington's disease:An open label study. Clin Neuropharmacol 25:263-265, 2002
2) Bymaster FP, Calligaro DO, Falcone JF, et al:Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96, 1996
3) Fumagalli F, Molteni R, Roceri M, et al:Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D asparte receptor activity. J Neurosci Res 72:622-628, 2003
4) 降旗隆二,久保英之,鈴木正泰,他:Huntington病に伴う幻覚妄想状態にRisperidoneが奏功した1例.東京精医雑誌 25:21-25,2007
5) Paleacu D, Anca M, Giladi N:Olanzapine in Huntington's disease. Acta Neurol Scand 105:441-444, 2002
6) Squitieri F, Cannella M:Short-term effects of olanzapine in Huntington's disease. Neuropsychiatry Neuropsychol Behav Neurol 14:69-72, 2001
7) van Vugt JP, Siesling S, van der Velde EA, et al:Clozapine versus placebo in Huntington's disease:A double blind randomized comparative sudy. J Neurol Neurosurg Psychiatry 63:35-39, 1997
8) Wakade CG, Mahadik SP, Waller JL, et al:Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 69:72-79, 2002
9) 山口高史,中澤隆弘,Bymaster FP:Multi-acting receptor targeted antipsychotic(MARTA)とは―olanzapineの薬理特性と臨床効果.臨精薬理 4:919-930,2001